MetrioPharm Press Releases
-
MetrioPharm AG Expands Patent Protection to Japan
Zurich, February 14, 2017. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in Japan.
-
Recruiting of MP1032’s Phase IIa trial in psoriasis successfully completed
MetrioPharm AG announces that dosing of the last patient in the clinical phase IIa trial MP1032-CT02 was started on October 20, 2016.
-
MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032
MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in two additional countries.
-
MetrioPharm AG reinforces its Management and Board for Further Growth
MetrioPharm AG announces that Dr. Sylvie Grégoire has been elected as the new Executive President of MetrioPharm's Board of Directors at the company's 10th Annual General Meeting.
-
MetrioPharm AG announces the first dosing of patients in the phase IIa clinical trial MP1032-CT02
MP1032 can inhibit inflammation by reducing the concentration of small proteins (cytokines) that are involved in the inflammation process in diseases such as chronic plaque psoriasis
-
Go-Ahead for the Clinical Phase II Trial
MetrioPharm AG announces the start of the clinical phase IIa trial in moderate-to-severe psoriasis for its lead molecule MP1032.
-
New basic patents granted for MP1032
MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in two additional countries.
-
Phase I successfully completed
MetrioPharm AG today announced positive results for all end points of its placebo controlled phase Ib clinical trial of the company’s lead drug MP1032.
-
Second part of Phase I Safety Study cleared by authorities
Following the completion of the single-dose segment in the MP1032 Phase I first-in-man study, the clinical and safety data from this trial were submitted by MetrioPharm to the German regulatory authority (BfArM) for a safety review.
-
Single-dose part of MP1032’s first-in-man clinical trial successful
MetrioPharm AG announces results of the single-dose part of its Phase I first-in-man clinical trial with its lead compound MP1032.